Improved endothelial function with metformin in type 2 diabetes mellitus.

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Research
• Pharmacology

Background:

• Type 2 diabetes mellitus is associated with impaired vascular endothelial function, potentially driven by insulin resistance.
• The impact of metformin, an insulin-sensitizing agent, on endothelial function in type 2 diabetes remains underreported.

Purpose of the Study:

• To evaluate the efficacy of metformin in improving endothelial function in patients with type 2 diabetes mellitus.
• To investigate the relationship between insulin resistance and endothelial dysfunction.

Main Methods:

• A 12-week randomized controlled trial comparing metformin (500 mg twice daily) with placebo in diet-treated type 2 diabetes patients without metabolic syndrome.
• Forearm plethysmography assessed blood flow responses to vasodilators (acetylcholine, sodium nitroprusside, verapamil).
• Whole-body insulin resistance was quantified using the homeostasis model assessment of insulin resistance (HOMA-IR).

Main Results:

• Metformin significantly improved acetylcholine-stimulated forearm blood flow, indicating enhanced endothelium-dependent function (p = 0.0027).
• No significant effects were observed on endothelium-independent vasodilation.
• Metformin treatment led to a significant reduction in HOMA-IR (32.5%, p = 0.01), with insulin resistance being the sole predictor of improved endothelial function (r = -0.659, p = 0.0012).

Conclusions:

• Metformin treatment effectively improves both insulin resistance and endothelial function in type 2 diabetes.
• A strong correlation exists between improvements in insulin resistance and endothelial function, supporting insulin resistance as a key factor in endothelial dysfunction.
• These findings have significant implications for the therapeutic strategies targeting vascular complications in type 2 diabetes.